Ion Beam Applications SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ion Beam Applications SA
JEFHCLON16: Growth Strategies And What's In Store Post-US Election
The Jefferies 2016 London Healthcare Conference, the largest health-care-dedicated investor meeting in Europe, took place this week in London. More than 140 pharma, biotech and medtech companies formally presented, and many more attended to meet and connect with investors and potential commercial partners. This article rounds up the best Tweets posted by the Medtech Insight team attending #JEFHCLON16. It includes insights from a panel session on what's in store for health care in the US post-election, as well as company updates from LivaNova, Smith & Nephew, Coloplast, Varian Medical Systems and bioMérieux.
Liquid Biopsy, Particle-Beam Radiotherapy Get 'Moonshot' Commitments
The White House announced 36 new project commitments under its ongoing Cancer Moonshot oncology initiative, including an ambitious project to create an open liquid-biopsy database and a NASA-NCI collaboration to explore the benefits of particle-beam radiotherapy.
IBA's Soaring Sales Underline Proton Therapy Demand
Ion Beam Applications continues to defend its lion's share of the proton therapy market, reporting double-digit topline growth for the first half of 2016 in spite of challenges in its more traditional radiotherapy offering.
Deals Shaping The Medical Industry, January 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
- Medical Devices
Diagnostic Imaging Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Modus Medical Devices Inc. (Modus QA)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.